AKT1 and glioblastoma: The CHI3L1 binding to CD44 activates several signaling pathways including mitogen-activated protein kinases/extracellular-signal-regulated kinases (MAPK/ERK, AKT/PKB), and Wnt/β-catenin signaling involved in neoplastic progression, which makes it a potential therapeutic target in cancers such as gastric cancer [57] and glioblastoma [58].